The present invention provides a method of treating fibromyalgia syndrome (FMS), chronic fatigue syndrome (CFS), and pain in an animal subject. The method generally involves administering a therapeutically effective amount of a dual serotonin norepinephrine reuptake inhibitor compound or a pharmaceutically acceptable salt thereof, wherein said dual serotonin norepinephrine reuptake inhibitor compound is characterized by a non-tricyclic structure and an equal or greater inhibition of norepinephrine reuptake than serotonin reuptake. In particular, the use of milnacipran to treat FMS, CFS, and pain is disclosed.

A invenção atual fornece um método de tratar o syndrome do fibromyalgia (FMS), o syndrome crônico da fatiga (CFS), e a dor em um assunto animal. O método envolve geralmente administrar uma quantidade therapeutically eficaz de um composto duplo do inibidor do reuptake do norepinephrine do serotonin ou de um sal pharmaceutically aceitável disso, wherein o composto duplo dito do inibidor do reuptake do norepinephrine do serotonin é caracterizado por uma estrutura non-non-tricyclic e por uma inibição igual ou mais grande do reuptake do norepinephrine do que o reuptake do serotonin. No detalhe, o uso do milnacipran tratar o FMS, o CFS, e a dor são divulgados.

 
Web www.patentalert.com

< Amine derivative compounds

< Dha-pharmaceutical agent conjugates to improve tissue selectivity

> Benzene tricarboxylic acid derivatives as insulin receptor activators

> Polysubstituted indan-1-ol systems for the prophylaxis or treatment of obesity

~ 00080